ReviewDrugs & aging2002
Role of hormones in the pathogenesis and management of sarcopenia.
Review in Drugs & aging, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 120 citations in OpenAlex.
- Trial
- Effect of resistance training on muscular strength and indicators of abdominal adiposity, metabolic risk, and inflammation in postmenopausal women: controlled and randomized clinical trial of efficacy of training volume.Age (Dordrecht, Netherlands) · 2016Trial
- A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia.The journal of nutrition, health & aging · 2013Trial
- Association of estimated muscle mass and its changes with all-cause mortality: a Chinese population-based cohort study.BMC geriatrics · 2026Article
- Can Dietary Supplements Support Muscle Function and Physical Activity? A Narrative Review.Nutrients · 2025Review
- Are Dietary Patterns Relevant for Reducing the Risk of Fractures and Sarcopenia?Current osteoporosis reports · 2025Review
- Muscle Organoid and Assembloid Systems.Advances in experimental medicine and biology · 2025Review
- Therapeutics for Sarcopenia and Functional Disabilities in Older Adults: A Review of Phase 4 Clinical Trials.Drug design, development and therapy · 2025Review
- Age-Related Influence on Static and Dynamic Balance Abilities: An Inertial Measurement Unit-Based Evaluation.Sensors (Basel, Switzerland) · 2024Article
- Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice.Cell death & disease · 2024Article
- Combination of selective androgen and estrogen receptor modulators in orchiectomized rats.Journal of endocrinological investigation · 2022Article
- Skeletal Muscle Metabolic Alternation Develops Sarcopenia.Aging and disease · 2022Review
- Association between dietary intake of branched-chain amino acids and sarcopenia and its components: a cross-sectional study.Scientific reports · 2022Article
- Sarcopenia in Chronic Pancreatitis - Prevalence, Diagnosis, Mechanisms and Potential Therapies.Current gastroenterology reports · 2022Review
- Understanding of sarcopenia: from definition to therapeutic strategies.Archives of pharmacal research · 2021Review
- Association between protoporphyrin IX and sarcopenia: a cross sectional study.BMC geriatrics · 2021Article
- Vascular dysfunction as a potential culprit of sarcopenia.Experimental gerontology · 2021Review
- Resistance Training in Hypoxia as a New Therapeutic Modality for Sarcopenia-A Narrative Review.Life (Basel, Switzerland) · 2021Article
- Gonadotropins at Advanced Age - Perhaps They Are Not So Bad? Correlations Between Gonadotropins and Sarcopenia Indicators in Older Adults.Frontiers in endocrinology · 2021Article
- Pharmacological Interventions for Treatment of Sarcopenia: Current Status of Drug Development for Sarcopenia.Annals of geriatric medicine and research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is growing evidence to indicate that age-related declines in growth hormone (GH), insulin-like growth factor (IGF)-1, and androgen and estrogen production play a role in the pathogenesis of sarcopenia (an age-related decline in muscle mass and quality). Although GH supplementation has been reported to increase lean body mass in elderly individuals, the high incidence of adverse effects combined with a very high cost has limited the applicability of this form of therapy. The assessment of an alternative approach to enhance the GH/IGF-1 axis in the elderly by using GH-releasing hormone and other secretagogues is currently under way and is showing some promise. Testosterone replacement therapy may increase muscle mass and strength and decrease body fat in hypogonadal elderly men. Long-term randomised, controlled trials are needed, however, to better define the risk-benefit ratio of this form of therapy before it can be recommended. Available data are currently insufficient to decide what role estrogen replacement therapy may play in the management of sarcopenia. Therefore, although the evidence linking age-related hormonal changes to the development of sarcopenia is rapidly growing, it is still too early to determine the clinical utility of hormonal supplementation in the management of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.